Research programme: anti-tuberculosis peptide therapeutics - Linnane Pharma
Latest Information Update: 03 Feb 2023
At a glance
- Originator Linnane Pharma
- Class Antituberculars; Peptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 04 Jan 2023 Preclinical trials in Tuberculosis in Sweden (unspecified route) as of January 2023 (Linnane Pharma pipeline, January 2023)
- 04 Jan 2023 Pharmacodynamics data from preclinical trial in Tuberculosis released by Linnane Pharma prior to January 2023
- 28 Jul 2022 Linnane Pharma has patent protection for peptides with antibiotic potential against Mycobacterium tuberculosis in the USA, Australia and Europe and patent pending in Canada